Brought to you by 
Roche to pay €130mm up front for cervical cancer diagnostics developer mtm
19 Aug 2011
Executive Summary
Roche is paying €130mm up front ($180mm) and up to €60mm in performance-related earn-outs for private cervical cancer testing company mtm Laboratories AG, which will become a division of the Big Pharma’s tissue-based diagnostics unit Ventana Medical Systems Inc. (part of Roche Diagnostics).
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Cytology
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche to pay €130mm up front for cervical cancer diagnostics developer mtm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice